कंपनी का अवलोकन
Establishment Labs Holdings Inc. operates within the healthcare sector, specifically functioning as a manufacturer and marketer of medical devices designed for breast aesthetic and reconstructive plastic surgeries across Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company's core business involves producing silicone gel-filled breast implants, serving a global market that spans multiple continents with significant operational reach. This entity is valued at a market capitalization of $1.82 billion, supported by an annual revenue stream of $211.08 million and a workforce comprising 1004 employees. The scale of these financial metrics, particularly the substantial market cap relative to its revenue base, indicates that the market assigns a high valuation multiple to the company's future growth potential and intangible assets rather than current cash flows. The disparity between the $1.82 billion market cap and the $211.08 million in trailing twelve-month revenue suggests that investors are pricing the stock based on expected future expansion and technological advantages in the medical device industry, rather than current profitability.
वित्तीय स्वास्थ्य
The company reported revenue of $211.08 million for the trailing twelve months, yet this revenue generated a net income of -$51,064,000 and an EBITDA of -$29,445,000. The significant gap between the $211.08 million in revenue and the negative net income reveals a cost structure where operating expenses, including research and development for new implant technologies, exceed the gross profit generated from sales. Free cash flow stands at -$41,574,000, which indicates that the company is currently burning cash, a situation that limits immediate financial flexibility but may be necessary for capital-intensive growth phases or product development cycles. The gross margin is reported at 69.3%, which suggests high pricing power and efficient production of medical devices, yet this is offset by a negative operating margin of -6.1% and a negative profit margin of -24.2%. These negative margins demonstrate that while the core product is profitable to manufacture, significant overhead costs are eroding the bottom line. The balance sheet shows $75.57 million in cash against $264.47 million in debt, resulting in a debt-to-equity ratio of 1123.14, which characterizes a highly leveraged financial position rather than a conservative one. Despite the high leverage, the current ratio of 3.04 indicates strong short-term liquidity, suggesting the company has ample current assets to cover its short-term liabilities. Furthermore, the return on equity is -133.3% and the return on assets is -6.9%, metrics that reveal that management has not yet generated returns on the capital invested, reflecting the company's current stage of development and profitability challenges.
मूल्यांकन आकलन
The valuation metrics show a trailing P/E ratio of N/A due to losses, while the forward P/E stands at 302.73, implying that the market is pricing in substantial future earnings growth to justify the current stock price. The price-to-book ratio is 77.19, indicating a significant market premium over the company's book value, which often occurs in high-growth sectors where assets are undervalued on traditional accounting measures. Additionally, the price-to-sales ratio is 8.62, and the EV/EBITDA is -68.21, suggesting that alternative valuation multiples are being used because traditional earnings-based metrics are not applicable. The stock has traded between a 52-week low of $26.56 and a 52-week high of $83.31, and without the current price explicitly stated in the provided facts, the valuation context relies on these historical boundaries to gauge volatility and potential range. The beta value of 1.08 indicates that the stock's price volatility is slightly higher than the broader market, moving 8% more than the market average in response to general market movements. This elevated beta combined with the high forward P/E suggests that the stock is sensitive to market sentiment and that any deviation from expected earnings growth could lead to significant price fluctuations.
Growth & Income
Revenue growth year-over-year is 45.2%, while earnings growth is N/A due to the company's current net loss status, implying that top-line expansion is outpacing profitability improvements as the business scales. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, as the payout ratio is 0.0%. This zero payout ratio reflects the company's strategy of reinvesting all available earnings and cash reserves into business expansion rather than distributing income to shareholders. The overall growth and income profile is defined by aggressive revenue expansion funded by external capital, as the company prioritizes market share and product development over immediate shareholder returns or dividend payments.